Rockwell Medical Announces Presentation Schedule for Triferic Clinical Posters at American Society of Nephrology (ASN) Meeting November 2015

WIXOM, Mich., Oct. 28, 2015 (GLOBE NEWSWIRE) — Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today the presentation schedule for four (4) Triferic clinical abstracts that will be presented at the ASN Kidney Week 2015 Annual Meeting, November 3-8 at the San Diego Convention Center in San Diego, CA. Triferic is the only FDA approved iron product indicated to replace iron and maintain hemoglobin in hemodialysis patients in the United States.

The following Triferic clinical presentations will be presented at ASN 2015:

Oral Presentation: Friday 11/6/2015; 4:30 PM – 6:30 PM; Session Room 6E   

Triferic Maintains Hemoglobin and Iron Balance Long-Term: Phase III Extension Studies 
Guss, C., Pratt, RD., Lin, V. and Gupta, A. 
Session Title: Balancing Erythropoiesis and Iron Load in CKD                   

Poster Presentations: Saturday 11/7/2015; 10:00 AM – 12:00 PM

Triferic has a Safety Profile Similar to Placebo: An Integrated Safety Analysis of Phase-2 and Phase-3 Studies 
Lin, V., et al. 
Session Title: Dialysis: Anemia and Iron Metabolism                     

Structural Physical and Functional Characteristics of Triferic (Ferric Pyrophosphate Citrate, FPC): A Novel Iron Compound for Pharmaceutical Applications 
Gupta, A., et al. 
Session Title: Dialysis: Anemia and Iron Metabolism                     

Triferic Does Not Induce Non-Transferrin Bound Iron or Labile Plasma Iron: In-Vivo/In-Vitro Correlation
Pratt, RD., et al.  
Session Title: Drug Pharmacokinetics and Pharmacogenomics in CKD

About Rockwell Medical

Rockwell Medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis.

Rockwell’s recent FDA approved drug Triferic is indicated for iron replacement and maintenance of hemoglobin in hemodialysis patients. Triferic delivers iron to patients during their regular dialysis treatment, using dialysate as the delivery mechanism. In completed clinical trials, Triferic has demonstrated that it safely and effectively delivers sufficient iron to the bone marrow and maintains hemoglobin, without increasing iron stores (ferritin). Rockwell intends to market Triferic to hemodialysis patients in the U.S. dialysis market.

Rockwell’s FDA approved generic drug Calcitriol is for treating secondary hyperparathyroidism in dialysis patients. Calcitriol (active vitamin D) injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy. Rockwell intends to market Calcitriol to hemodialysis patients in the U.S. dialysis market.

Rockwell is also an established manufacturer and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad. As one of the two major suppliers in the U.S., Rockwell’s products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient’s bloodstream. Rockwell has three manufacturing/distribution facilities located in the U.S.

Rockwell’s exclusive renal drug therapies support disease management initiatives to improve the quality of life and care of dialysis patients and are intended to deliver safe and effective therapy, while decreasing drug administration costs and improving patient convenience. Rockwell Medical is developing a pipeline of drug therapies, including extensions of Triferic for indications outside of hemodialysis. Please visit www.rockwellmed.com for more information.

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Rockwell’s intention to launch Calcitriol and Triferic following FDA approval. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan”, “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in Rockwell Medical’s SEC filings. Thus, actual results could be materially different. Rockwell Medical expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

Triferic® is a registered trademark of Rockwell Medical, Inc.

CONTACT: Michael Rice, Investor Relations: 646-597-6979